Aarti Drugs Ltd

- No explicit mention of new fundraising through debt or equity in the transcript. - The company incurred capex of INR 52 crores during Q1 FY25, mainly funded through internal accruals and partly through term loans. - Anticipated total capex for FY25 is INR 200 crores, expected to be funded mainly through internal accruals and partly through term loans. - No indication of fresh equity issuance or external debt raising plans beyond existing term loans mentioned for capex. - Management did not highlight any upcoming fundraise for expansion or other purposes during the call.

- INR 52 crores capex incurred in Q1 FY'25 for capacity expansion, backward integration, and new product launches in formulation. - Total capex guidance for FY'25 is INR 200 crores, funded through internal accruals and partly through term loans. - Two Greenfield projects nearing completion: one in Saykha (specialty chemicals and intermediates) expected by end Q2 FY'25; another minor component related to salicylic acid plot development. - Brownfield expansions underway: Baddi facility formulation capacity to increase by 15-20% next quarter and potentially double in 12-15 months. - Ongoing R&D on formulation side focusing on new product development (oncology, cardiac, diabetic) for launches in next 2-3 years. - Saykha Greenfield project capex mostly complete; minor residual capex expected this year. - Metformin capacity expansion planned from current 1,400-1,500 tons/month to 1,700-1,800 tons/month, pending environmental approvals.

- The company aims to achieve over INR 4,000 crores in revenue within the next 3-4 years, based on current prices and volume growth. - API volume growth was flat in H1 FY'25 but expected to rebound to mid-teens percentage growth in H2 FY'25. - Specialty Chemicals segment is projected to grow about 50% year-on-year in H2 FY'25 as new capacities come online. - Formulation export business is growing due to new product launches and market expansions, with international business expected to offset domestic declines, supporting double-digit growth in formulations. - Oncology formulations are expected to begin contributing initial sales from FY'26 with major contributions from FY'27. - Continuous increase in capacity, including expansions in Baddi and Saykha, will support growth. - Margins expected to improve to 14-15% EBITDA long-term with better operating leverage and backward integration.

- Aarti Drugs aims to achieve revenues upwards of INR 4,000 crores in the next 3-4 years (FY'27 target) based on volume growth and current pricing. - Long-term EBITDA margins are targeted between 14% to 15%. - Volume growth is expected to recover in H2 FY'25, with mid-teens growth for API business anticipated in the second half. - Specialty Chemicals segment is expected to see ~50% year-on-year growth in H2 FY'25 as new capacities come online. - Formulation exports are increasing with new product launches and new markets, offsetting domestic shifts; oncology formulations expected to start contributing sales from FY'26. - Capex of INR 200 crores planned for FY'25, focused on capacity expansion, backward integration, and new product launches, which will support margin improvement. - Operating leverage and improved capacity utilization from new Greenfield projects expected to boost margins and profits in the second half of FY'25 and beyond.

- The export orders have a pending order book of approximately 2.5 to 3 months. - Export orders executed in March quarter were based on orders from December quarter when prices were higher. - The June quarter orders executed were placed in March quarter when prices had fallen, leading to observed price decline in exports. - Domestic order book is less than 1 month, showing quicker price reflection. - Export demand remained subdued in Q1 and Q2 FY25 with expectations of improvement from Q3 onwards.